NDAORALTABLETPriority Review
Approved
Jun 1990
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 8h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ERGAMISOL (levamisole hydrochloride) is an oral small-molecule anthelmintic agent approved in 1990 for parasitic infections. The drug works as an immunostimulant and antiparasitic, enhancing immune function while eliminating helminth infections. It is primarily used in nematode and certain cestode infections.
LOE Approaching
Product is in late-stage lifecycle with moderate competitive pressure (30%), suggesting defensive positioning and potential team consolidation.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on ERGAMISOL offers limited career growth due to zero linked job openings and approaching loss of exclusivity. Positions on this product are typically focused on defending market share and managing transition to generic competition rather than launching or expanding.
Brand ManagerField Sales Representative
Worked on ERGAMISOL at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.